Skip to content
Clinical Trials – home
SwedenBack to Sweden

Clinical trials in Höllviken – page 88

1 391 clinical trials in Höllviken, Sweden. Every trial is listed in the EU Clinical Trials Register and updated daily.

SwedenOur site in SwedenKliniska-Provningar.se(opens in a new tab)
Höllviken at a glance
1 391
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 391 trials in Höllviken

Open in trial search

Study of NIDO-361 for Patients with Spinal and Bulbar Muscular Atrophy (SBMA)

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:NIDO-361
  • Sponsor:Nido Biosciences Inc.

Phenylketonuria

Not recruiting

Study on the Long-Term Safety of PTC923 (Sepiapterin) for Patients with Phenylketonuria

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Sepiapterin
  • Sponsor:PTC Therapeutics Inc.

Bladder cancer

Not recruiting

Study of Pembrolizumab and Enfortumab Vedotin with Surgery vs. Surgery Alone for Patients with Muscle-Invasive Bladder Cancer Who Cannot or Choose Not to Use Cisplatin

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Merck Sharp & Dohme LLC

Study on Siplizumab and Rabbit Anti-Thymocyte Globulin for Preventing Rejection in New Kidney Transplant Patients

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Paracetamol
  • Sponsor:Itb-Med AB

Study of Epcoritamab for Patients with Relapsed, Progressive, or Refractory B-Cell Lymphoma

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Anakinra
  • Sponsor:Genmab A/S

Study of Nivolumab and Relatlimab for Patients with Stage III-IV Melanoma After Surgery

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol Myers Squibb International Corporation

Study of Amivantamab, Lazertinib, and Drug Combination for Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer After Osimertinib Failure

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

Study on the Safety and Effectiveness of Ocrelizumab vs. Fingolimod for Children and Adolescents with Relapsing-Remitting Multiple Sclerosis

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Dimenhydrinate
  • Sponsor:F. Hoffmann-La Roche AG

Neoplasm

Not recruiting

Study on Repotrectinib for Children and Young Adults with Advanced Solid Tumors with ALK, ROS1, or NTRK1-3 Alterations

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years
  • Substances:Repotrectinib
  • Sponsor:Turning Point Therapeutics Inc.

Asthma

Not recruiting

Study on the Effectiveness and Safety of AZD4604 for Adults with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA

Investigational
Countries:SwedenSweden
  • Participants:18–64 years
  • Substances:Londamocitinib xinafoate
  • Sponsor:AstraZeneca AB

Factor VIII deficiency+1

Not recruiting

Study on How Concizumab Works for Patients with Hemophilia A or B Without Inhibitors

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Concizumab
  • Sponsor:Novo Nordisk A/S

Multiple sclerosis+1

Not recruiting

Study on the Effects of a Higher Dose of Ocrelizumab for Adults with Primary Progressive Multiple Sclerosis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Methylprednisolone
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in Sweden

The busiest research cities in the country

All 66 cities in Sweden

Clinical research in Höllviken

What the registry says about research in the country

01 Respiratory Medicine

Innovative research focusing on Chronic Obstructive Pulmonary Disease (COPD) management through advanced combination therapy approaches. The studies aim to evaluate triple therapy effectiveness compared to dual bronchodilator treatments for improving cardiopulmonary outcomes.

  • Respiratory Disease Management
  • Cardiopulmonary Health
  • Therapeutic Combinations

These trials explore enhanced treatment options for patients with chronic respiratory conditions, focusing on improving their quality of life through optimized medication combinations.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.